<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Infliximab (IFX) is currently the only biologic therapy used in the treatment of moderate-to-severe <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> (UC) </plain></SENT>
<SENT sid="1" pm="."><plain>In the years to come, more biologic therapies will have a role in the management of moderate-to-severe UC </plain></SENT>
<SENT sid="2" pm="."><plain>We report on two patients with steroid-dependent UC who, due to adverse reactions to IFX, have been under therapy with adalimumab for two years </plain></SENT>
<SENT sid="3" pm="."><plain>Both patients received concomitant immunosuppressive treatment </plain></SENT>
<SENT sid="4" pm="."><plain>Long term clinical remission and mucosal healing are described </plain></SENT>
</text></document>